{"entity":{"id":"bi-1910","kind":"drug","name":"BI-1910","aka":[],"tldr":"BI-1910 is an experimental monoclonal antibody from BioInvent International, in phase 2 trials for advanced solid tumours, non-small-cell lung cancer and hepatocellular carcinoma.","summary":"BI-1910 is a monoclonal antibody (agonist) from BioInvent International, with Merck & Co. as partner. An agonist anti-TNFR2 antibody, described by BioInvent as a differentiated agonist approach compared with its antagonist anti-TNFR2 antibody BI-1808; tested alone and with pembrolizumab in solid tumours. Its furthest stage is phase 2, for advanced solid tumours, non-small-cell lung cancer and hepatocellular carcinoma. ClinicalTrials.gov registers it in one study linked below. Phase 1/2a NCT06205706 active, not recruiting (registry, checked 3 Nov 2026). Company page says phase 2a single-agent work was planned for H1 2025 including HCC. Whether it works in people has not been established unless a trial below reports it.","status":"phase-2","asOf":"2026-11-03","links":[{"label":"BioInvent International: bioinvent.com","url":"https://www.bioinvent.com/en/clinical-programs/our-programs/bi-1910"},{"label":"BioInvent International: bioinvent.com","url":"https://www.bioinvent.com/en/clinical-programs/our-programs/bi-1910"},{"label":"ClinicalTrials.gov: trials of BI-1910","url":"https://clinicaltrials.gov/search?intr=BI-1910"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer","nsclc","hcc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["bioinvent-international","merck"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06205706"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"BI-1910","modality":"Monoclonal antibody (agonist)","mechanism":"An agonist anti-TNFR2 antibody, described by BioInvent as a differentiated agonist approach compared with its antagonist anti-TNFR2 antibody BI-1808; tested alone and with pembrolizumab in solid tumours.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/bi-1910/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"company":[{"id":"bioinvent-international","kind":"company","name":"BioInvent International","route":"/companies/bioinvent-international/"},{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}],"trial":[{"id":"nct06205706","kind":"trial","name":"BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors","route":"/trials/nct06205706/"}]}}